The Longevity Fund

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, developing in vivo gene correction therapies for cancer and infectious diseases.

Unity Biotechnology was a biotechnology company focused on developing therapeutics to extend healthspan by targeting cellular senescence.

Arda Therapeutics is focused on targeting pathogenic cells to treat chronic diseases using advanced single-cell data analysis to design therapies that specifically eliminate these cells.

General Proximity is a biotech company pioneering next-gen proximity medicines, focusing on undruggable targets using its OmniTAC platform.

Reservoir Neuroscience develops therapeutics to heal the blood-brain barrier.

Conception is pioneering a stem cell technology known as in-vitro gametogenesis (IVG) to transform stem cells into viable human eggs. This innovative approach aims to assist families facing infertility, enable older couples to have biological children, and potentially reduce the risk of genetic diseases in future generations.

Skeletalis Bio is focused on developing targeted therapies for osteoporosis treatment, utilizing a small-molecule platform called OASIS to enhance bone health and rebuild skeletal resilience.

Untillabs is a moonshot company developing a 'pause button' for biology, aiming to innovate in the life sciences sector. They focus on creating groundbreaking solutions that could transform biological processes and research.

Science Corporation is a clinical-stage medical technology company focused on brain-computer interfaces and neural engineering. It develops advanced hardware for research and medical applications, aiming to restore quality of life for those with debilitating conditions.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.